What drugs does Sumitomo make?
Sumitomo Pharma manufactures and commercializes a broad portfolio of pharmaceutical products focusing on psychiatry, neurology, oncology, and regenerative medicine. Its major commercial prescription drugs include Latuda for schizophrenia and bipolar depression, Myfembree and Oriahnn for uterine fibroids and endometriosis, and Kynmobi for Parkinson disease off episodes. Through advanced research initiatives, the enterprise also develops cell and gene therapies and oncology treatments designed to address complex unmet medical needs globally.
Related FAQs
Sumitomo Corporation and its diverse network of group companies constitute one of the world's largest general trading and manufacturing enterprises, producing an extraordinarily broad spectrum of industrial and consumer goods.
Market analyst consensus ratings for Sumitomo Chemical India frequently feature positive buy recommendations, with equity researchers highlighting robust fundamental operations, expanding distribution footprints, and strong product demand in agricult...
Sumitomo Chemical Co., Ltd.
Sumitomo Chemical Co., Ltd. is a major Japanese multinational chemical enterprise that manufactures an extensive portfolio of advanced chemical products, agricultural solutions, petrochemicals, IT-related materials, and pharmaceutical drugs.
Sumitomo Chemical is recognized globally as a major, highly diversified chemical enterprise producing essential agricultural solutions, pharmaceuticals, electronic materials, and advanced chemical products.
Sumitomo Chemical Company, Limited operates as an independent, publicly traded multinational chemical enterprise headquartered in Tokyo, Japan, meaning it is not owned by an external corporate parent.
Sunny Optical Technology Group operates as a leading global designer and manufacturer of optical and optical-related products, generating its substantial revenue primarily through three core business segments: optical lenses, handset camera modules, ...
Sumitomo Chemical maintains a variable annualized dividend yield influenced by fluctuating commodity chemical cycles, agricultural market dynamics, and periodic corporate restructuring outcomes.
Equity research analysts tracking Sumitomo Chemical maintain a balanced consensus rating, blending hold and moderate buy recommendations as the multinational chemical enterprise navigates complex global agricultural and specialty materials cycles.